Table 1 Parameters after the administration of uric acid-lowering drugs
From: Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia
Febuxostat | Benzbromarone | |||||||
|---|---|---|---|---|---|---|---|---|
Uric acid-lowering drug | Baseline | 3 M (Feb) | 6 M (Feb/Ben) | 9 M (Ben) | Baseline | 3 M (Ben) | 6 M (Feb/Ben) | 9 M (Feb) |
eGFR (ml min−1 1.73 m−2) | 66±26 | 66±25 | 66±26 | 66±27 | 56±21 | 55±18 | 55±22 | 54±20 |
Uric acid (mg dl−1) | 6.9±1.1 | 4.3±1.1 | 3.6±0.9 | 4.3±1.1 | 7.7±1.5 | 5.1±1.3 | 4.5±0.9 | 5.1±1.0 |
UUA/UCr | 0.35±0.12 | 0.18±0.08 | 0.27±0.14 | 0.45±0.14 | 0.46±0.34 | 0.44±0.11 | 0.30±0.11 | 0.28±0.18 |
EUA (mg kg−1 h−1) | 0.26±0.07 | 0.14±0.12 | 0.28±0.29 | 0.34±0.08 | 0.31±0.12 | 0.46±0.24 | 0.22±0.10 | 0.15±0.07 |
CUA (ml min−1) | 4.33±1.35 | 3.75±3.33 | 8.68±6.79 | 9.46±3.93 | 5.05±2.63 | 11.07±6.09 | 5.81±3.10 | 3.39±1.63 |
UAE (mg per gCr) | 16±23 | 12±14 | 11±13 | 15±23 | 312±856 | 249±697 | 310±859 | 338±894 |
Urinary 8-OHdG (ng per mlCr) | 12.5±4.0 | 12.6±4.6 | 11.3±2.9 | 11.4±5.0 | 11.5±5.2 | 8.3±2.1 | 11.3±2.4 | 10.6±1.8 |
MCP-1 (pg ml−1) | 287±95 | 296±59 | 299±90 | 305±99 | 253±70 | 273±83 | 271±62 | 289±69 |
LFABP (μg per g•Cr) | 2.7±1.6 | 5.1 | 3.1±1.6 | 2.9±1.0 | 12.5±8.1 | 8.1±3.5 | 13.3±10.5 | 11.7±6.6 |
Flow-mediated dilation (%) | 4.5±1.8 | 4.9±1.9 | 6.2±2.3 | 5.3±2.6 | 4.4±1.9 | 5.8±3.7 | 5.2±2.7 | 4.7±1.7 |
Renal artery resistive index | 0.66±0.06 | 0.66±0.06 | 0.67±0.06 | 0.68±0.06 | 0.65±0.07 | 0.65±0.05 | 0.67±0.05 | 0.67±0.05 |
